Feasibility of Modified FOLFOX in Elderly Patients Aged ≥80 Years with Metastatic Gastric Cancer or Colorectal Cancer

Publisher： Karger

E-ISSN： 1423-0232|93|2|115-121

ISSN： 0030-2414

Source： Oncology, Vol.93, Iss.2, 2017-04, pp. : 115-121

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dietary Methionine Restriction with FOLFOX Regimen as First Line Therapy of Metastatic Colorectal Cancer: A Feasibility Study

By  

Oncology, Vol. 78, Iss. 3-4, 2010-04 ,pp. : 205-209

Karger

Access to resources Recommend Favorite

Tumour characteristics, treatment patterns and survival of patients aged 80 years or older with colorectal cancer

By  

COLORECTAL DISEASE, Vol. 17, Iss. 3, 2015-03 ,pp. : 205-215

John Wiley & Sons Inc

Access to resources Recommend Favorite

TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first‐line treatment of metastatic colorectal cancer

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4290-4298

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cetuximab plus FOLFOX for Patients with Metastatic Colorectal Cancer with Poor Performance Status and/or Severe Tumor-Related Complications

By  

Case Reports in Oncology, Vol. 3, Iss. 2, 2010-07 ,pp. : 282-286

Karger

Access to resources Recommend Favorite

Reply to: Surgical treatment of colon cancer in patients aged 80 years and older

By  

CANCER, Vol. 119, Iss. 18, 2013-09 ,pp. : 3419-3419

John Wiley & Sons Inc

Access to resources Recommend Favorite